Free Trial
NASDAQ:CODX

Co-Diagnostics Q2 2025 Earnings Report

Co-Diagnostics logo
$0.25 0.00 (-1.91%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$0.26 +0.01 (+4.99%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Co-Diagnostics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.25
Beat/Miss
N/A
One Year Ago EPS
N/A

Co-Diagnostics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.30 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Co-Diagnostics Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Co-Diagnostics Earnings Headlines

Co-Diagnostics (CODX) to Release Earnings on Thursday
Protect Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
CODX Co-Diagnostics, Inc. - Seeking Alpha
See More Co-Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Co-Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Co-Diagnostics and other key companies, straight to your email.

About Co-Diagnostics

Co-Diagnostics (NASDAQ:CODX), a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

View Co-Diagnostics Profile

More Earnings Resources from MarketBeat